Beijing Biostar Pharmaceuticals Looks to Raise Up to HK$321 Million from Hong Kong IPO

MT Newswires Live10-23

Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.

The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.

Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.

The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.

Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.

CCB International, China Securities International, ICBC, SPDB International, and several others are the joint book-runners of the IPO.

Price (HKD): $2761.00, Change: $+1.2, Percent Change: +0.04%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477731702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-23 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477731702","market":"us","top_or_hot":-1,"title":"Beijing Biostar Pharmaceuticals Looks to Raise Up to HK$321 Million from Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.</p><p>The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.</p><p>Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.</p><p>The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.</p><p>Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.</p><p>CCB International, China Securities International, ICBC, SPDB International, and several others are the joint book-runners of the IPO.</p><p>Price (HKD): $2761.00, Change: $+1.2, Percent Change: +0.04%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Biostar Pharmaceuticals Looks to Raise Up to HK$321 Million from Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Biostar Pharmaceuticals Looks to Raise Up to HK$321 Million from Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-23 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.The pharmaceutical is offering 14,588,000 H shares at HK$16 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477731702","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477731702","pubTimestamp":1729647136,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Beijing Biostar Pharmaceuticals  launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.CCB International, China Securities International, ICBC, SPDB International, and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","02563":"华昊中天医药－Ｂ","BK1560":"内银股","BK1231":"综合性银行","LU0823426308.USD":"法巴中国股票基金","LU0737861699.HKD":"FIDELITY CHINA FOCUS \"A \" (HKD) ACC","BK4588":"碎股","BK4526":"热门中概股","HKD":"尚乘数科","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU1880383440.USD":"AMUNDI FUNDS CHINA EQUITY \"A2\" (USD) INC","01398":"工商银行","BK1521":"挪威政府全球养老基金持仓","LU0823426480.USD":"法巴中国股票经典Dis","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0173614495.USD":"富达中国焦点A","LU0359201612.USD":"贝莱德中国基金A2","03143":"华夏香港银行股","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1224709979.USD":"FIDELITY CHINA FOCUS \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK4023":"应用软件","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC"},"translate_title":"北京映泰制药拟香港IPO募资至多3.21亿港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"02563":0.9,"01398":0.67,"03143":0.6},"content_text":"Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.CCB International, China Securities International, ICBC, SPDB International, and several others are the joint book-runners of the IPO.Price (HKD): $2761.00, Change: $+1.2, Percent Change: +0.04%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477731702"}